ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Ghosh on the Role of Bleomycin in Hodgkin Lymphoma

Nilanjan Ghosh, MD, PhD
Published: Tuesday, Jun 05, 2018



Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.

Ghosh says that he and many investigators are actively working on reducing bleomycin exposure or eliminating the agent completely from the frontline setting of Hodgkin lymphoma. Bleomycin can cause significant pulmonary toxicity that can be irreversible in some cases, Ghosh explains.

The recent RATHL trial randomized patients to doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) versus adriamycin, vinblastine, and dacarbazine (AVD). Ghosh says that since there was no significant difference in progression-free survival between the 2 groups, bleomycin does not need to be used in these patients. Additionally, most clinicians who are doing PET-adaptive therapy drop bleomycin after 2 cycles if the PET scan is negative.


Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.

Ghosh says that he and many investigators are actively working on reducing bleomycin exposure or eliminating the agent completely from the frontline setting of Hodgkin lymphoma. Bleomycin can cause significant pulmonary toxicity that can be irreversible in some cases, Ghosh explains.

The recent RATHL trial randomized patients to doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) versus adriamycin, vinblastine, and dacarbazine (AVD). Ghosh says that since there was no significant difference in progression-free survival between the 2 groups, bleomycin does not need to be used in these patients. Additionally, most clinicians who are doing PET-adaptive therapy drop bleomycin after 2 cycles if the PET scan is negative.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x